SuanFarma-Header

SuanFarma-Header

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Reset Filter

All Drugs in Dev.

Product Type

Companies

Viralgen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Post An Enquiry

Mediterranean Congress of Chemical

Participation Not Confirmed

Update your events

Axovant and Viralgen Sign Strategic Gene Therapy Development and Manufacturing Partne...

Lead Product(s): AXO-AAV-GM1

Therapeutic Area: Genetic Disease Product Name: AXO-AAV-GM1

Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Axovant Gene Therapies

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership September 15, 2020

Details:

Axovant will have access to manufacturing resources for Axovant’s AAV-based gene therapy programs, AXO-AAV-GM1 for GM1 gangliosidosis and AXO-AAV-GM2 for GM2 gangliosidosis with sufficient capacity to support ongoing development and eventual commercialization.